Functional studies using orthogonal preclinical models revealed a synergistically antitumor response when TIGIT/PD-1 co-blockade was combined with CD40 agonism because they had been reinvigorated tumor-reactive T cells (158). The gene discussed is TIGIT; the disease is neoplasm.